Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
US Army
Julphar
Chinese Patent Office
US Department of Justice
UBS
Queensland Health
Healthtrust
Johnson and Johnson

Generated: January 19, 2018

DrugPatentWatch Database Preview

NIMBEX Drug Profile

« Back to Dashboard

When do Nimbex patents expire, and when can generic versions of Nimbex launch?

Nimbex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIMBEX is cisatracurium besylate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
Summary for NIMBEX
Drug patent expirations by year for NIMBEX
Pharmacology for NIMBEX

US Patents and Regulatory Information for NIMBEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-003 Dec 15, 1995 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NIMBEX PRESERVATIVE FREE cisatracurium besylate INJECTABLE;INJECTION 020551-002 Dec 15, 1995 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NIMBEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 ➤ Subscribe ➤ Subscribe
Abbvie NIMBEX cisatracurium besylate INJECTABLE;INJECTION 020551-001 Dec 15, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NIMBEX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 8/4/2009
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 8/12/2009

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
Daiichi Sankyo
Mallinckrodt
Cipla
Fuji
Julphar
Teva
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot